Literature DB >> 2787862

The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies.

R A Fields1, H Toubbeh, R P Searles, A D Bankhurst.   

Abstract

The presence of anticardiolipin antibodies (aCL) has been associated with arterial and venous thrombotic events in connective tissue diseases. Previous investigations have suggested an increased incidence of aCL in the elderly population. We have studied the prevalence of aCL in large groups of 300 healthy elderly (mean age 70) and 543 younger subjects. aCL were determined by ELISA for the presence of IgG and IgM antibodies and was detected in 37 individuals (12%). This compared with an overall prevalence in a younger population of 2%. In addition, aCL was detected in 23% of elderly individuals who were also positive test for antinuclear antibodies (ANA). There was, however, no correlation with the presence of rheumatoid factor or lymphocytotoxic antibodies in this elderly group. Therefore, aCL have increased prevalence in an elderly population, and were associated with a positive test for ANA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787862

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

2.  Histological appearance of the intra-osseous vessels of the femoral head in aseptic osteonecrosis of the hip, with or without antiphospholipid antibodies.

Authors:  M Laroche; I Ludot; M Thiechart; G Viguier; C Dromer; B Mazières
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 3.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  The prevalence of autoantibodies in an elderly sub-Saharan African population.

Authors:  R Njemini; I Meyers; C Demanet; J Smitz; M Sosso; T Mets
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

5.  Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.

Authors:  P Gargiulo; J Goldberg; B Romani; R Schiaffini; P Ciampalini; W P Faulk; J A McIntyre
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

6.  Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus.

Authors:  H W Jones; R Ireland; G Senaldi; F Wang; M Khamashta; A J Bellingham; K Veerapan; G R Hughes; D Vergani
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

Review 7.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

8.  Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.

Authors:  C L Yu; K H Sun; C Y Tsai; S R Wang
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

9.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

Review 10.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.